{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:44:41Z","timestamp":1793857481003,"version":"4.6.1"},"reference-count":50,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"unspecified","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82574898"],"award-info":[{"award-number":["82574898"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["ZCLMS25H2705"],"award-info":[{"award-number":["ZCLMS25H2705"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2026,1,21]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Dyslipidaemia in systemic lupus erythematosus (SLE) contributes to pathogenesis and cardiovascular risk. The effect of statin therapy on SLE disease activity remains controversial. This meta-analysis systematically evaluates the impact of statins on SLE activity and inflammatory markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study adhered to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. A systematic literature search across multiple databases was conducted up to 13 November 2024. Study selection, data extraction and quality assessment were performed independently by two reviewers. Meta-analysis was conducted using R software, evaluating outcomes including SLE Disease Activity Index (SLEDAI), C-reactive protein (CRP), interleukin-6 (IL-6) and erythrocyte sedimentation rate (ESR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 3596 identified records, 12 studies were included. Statins significantly reduced SLEDAI in controlled before-after studies (weighted mean difference (WMD)=\u22120.70, 95%\u2009CI \u22121.16 to \u22120.23; p=0.0037), but not in parallel controlled trials (WMD=\u22120.58, 95%\u2009CI \u22121.74 to 0.59; p=0.330; I\u00b2 = 81.1%). Subgroup analysis showed a pronounced reduction in patients with a mean age &lt;40 years (WMD=\u22121.60, 95%\u2009CI \u22121.98 to \u22121.22; p&lt;0.001). Statins lowered CRP in both controlled before-after studies (standardised mean difference (SMD)=\u22120.38, 95%\u2009CI \u22120.73 to \u22120.03; p=0.032) and parallel controlled trials (SMD=\u22121.45, 95%\u2009CI \u22122.84 to \u22120.07; p=0.040). After excluding an outlier, the reduction in IL-6 became significant (SMD=\u22120.32, 95%\u2009CI \u22120.63 to \u22120.00; p=0.048). ESR was also reduced (SMD=\u22121.81, 95%\u2009CI \u22123.54 to \u22120.08; p=0.0406). No significant publication bias was detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Statin therapy may reduce disease activity and inflammation in SLE, with a consistent benefit observed in patients with a mean age &lt;40 years. Significant heterogeneity underscores the need for future rigorously designed, age-stratified randomised trials to confirm these findings and define the target patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42025630267<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2025-001770","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:45:55Z","timestamp":1770651955000},"page":"e001770","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Statin therapy in systemic lupus erythematosus: a meta-analysis of disease activity and inflammatory biomarkers"],"prefix":"10.1136","volume":"13","author":[{"given":"Suhai","family":"Qian","sequence":"first","affiliation":[{"name":"School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Hu","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Luo","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runyu","family":"Chang","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China"},{"name":"School of Nursing, Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7090-9445","authenticated-orcid":false,"given":"Xinghong","family":"Ding","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"2026072811151242000_13.1.e001770.1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)00398-2"},{"key":"2026072811151242000_13.1.e001770.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00668-1"},{"key":"2026072811151242000_13.1.e001770.3","doi-asserted-by":"crossref","first-page":"6917","DOI":"10.2147\/JIR.S339744","article-title":"An Analysis of the Correlation Between Clinical Indexes and Pathological Classifications in 202 Patients with Lupus Nephritis","volume":"14","author":"Pan","year":"2021","journal-title":"J Inflamm Res"},{"key":"2026072811151242000_13.1.e001770.4","doi-asserted-by":"crossref","first-page":"1503434","DOI":"10.3389\/fimmu.2024.1503434","article-title":"Serum lipid profile in systemic lupus erythematosus","volume":"15","author":"Xuan","year":"2025","journal-title":"Front Immunol"},{"key":"2026072811151242000_13.1.e001770.5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41581-023-00797-8","article-title":"Vascular damage in systemic lupus erythematosus","volume":"20","author":"Ambler","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"2026072811151242000_13.1.e001770.6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/joim.13557","article-title":"Systemic lupus erythematosus and cardiovascular disease","volume":"293","author":"Frosteg\u00e5rd","year":"2023","journal-title":"J Intern Med"},{"key":"2026072811151242000_13.1.e001770.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2010.04.010"},{"key":"2026072811151242000_13.1.e001770.8","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.3390\/ijms22052291","article-title":"Vascular Inflammation and Dysfunction in Lupus-Prone Mice-IL-6 as Mediator of Disease Initiation","volume":"22","author":"Marczynski","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026072811151242000_13.1.e001770.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.10.002"},{"key":"2026072811151242000_13.1.e001770.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-016-1252-4"},{"key":"2026072811151242000_13.1.e001770.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204351"},{"key":"2026072811151242000_13.1.e001770.12","first-page":"162","article-title":"Effects of statins on proinflammatory\/prothrombotic biomarkers and on disease activity scores in SLE patients: data from LUMINA (LXXVI), a multi-ethnic US cohort","volume":"32","author":"Willis","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2026072811151242000_13.1.e001770.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200071"},{"key":"2026072811151242000_13.1.e001770.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.23605"},{"key":"2026072811151242000_13.1.e001770.15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.autrev.2015.12.007","article-title":"Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: A systematic review and meta-analysis of controlled trials","volume":"15","author":"Sahebkar","year":"2016","journal-title":"Autoimmun Rev"},{"key":"2026072811151242000_13.1.e001770.16","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s10067-014-2654-7","article-title":"Atorvastatin effect on systemic lupus erythematosus disease activity: a double-blind randomized clinical trial","volume":"33","author":"Fatemi","year":"2014","journal-title":"Clin Rheumatol"},{"key":"2026072811151242000_13.1.e001770.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026072811151242000_13.1.e001770.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780251101"},{"key":"2026072811151242000_13.1.e001770.19","first-page":"117","article-title":"Advanced methods of data extraction for continuous outcomes in meta-analysis","volume":"17","author":"Liu","year":"2017","journal-title":"Chinese Journal of Evidence-Based Medicine"},{"key":"2026072811151242000_13.1.e001770.20","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20f13681"},{"key":"2026072811151242000_13.1.e001770.21","doi-asserted-by":"publisher","DOI":"10.2188\/jea.15.235"},{"key":"2026072811151242000_13.1.e001770.22","doi-asserted-by":"publisher","DOI":"10.2307\/2533446"},{"key":"2026072811151242000_13.1.e001770.23","first-page":"1572","article-title":"Simvastatin reduces antiphospholipid antibodies formation in patients with systemic lupus erythematosus: a preliminary study","volume":"27","author":"Kotyla","year":"2018","journal-title":"Lupus (Los Angel)"},{"key":"2026072811151242000_13.1.e001770.24","first-page":"355","article-title":"Short-term atorvastatin therapy improves arterial stiffness of middle-aged systemic lupus erythematosus patients with pathological pulse wave velocity","volume":"26","author":"Castejon","year":"2017","journal-title":"Lupus (Los Angel)"},{"key":"2026072811151242000_13.1.e001770.25","first-page":"6","article-title":"Low dose of simvastatin reduces disease activity and improves endothelial function in patients with systemic lupus erythematosus","volume":"37 Suppl 122","author":"Kotyla","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2026072811151242000_13.1.e001770.26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/295239","article-title":"Effects of Atorvastatin on Atherosclerosis and Atherogenesis in Systemic Lupus Erythematosus: A Pilot Study","volume":"2014","author":"Sokoll","year":"2014","journal-title":"ISRN Immunology"},{"key":"2026072811151242000_13.1.e001770.27","doi-asserted-by":"crossref","DOI":"10.1186\/ar3402","article-title":"Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study","volume":"13","author":"Plazak","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2026072811151242000_13.1.e001770.28","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.136762"},{"key":"2026072811151242000_13.1.e001770.29","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-007-0341-6"},{"key":"2026072811151242000_13.1.e001770.30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem186"},{"key":"2026072811151242000_13.1.e001770.31","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.81511"},{"key":"2026072811151242000_13.1.e001770.32","first-page":"141","article-title":"Clinical efficacy of hydroxychloroquine combined with atorvastatin in patients with systemic lupus erythematosus and its influence on the activity of lupus","volume":"6","author":"Zheng","year":"2019","journal-title":"Electronic Journal of Clinical Medical Literature"},{"key":"2026072811151242000_13.1.e001770.33","first-page":"927","article-title":"Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus","volume":"19","author":"Ferreira","year":"2010","journal-title":"Lupus (Los Angel)"},{"key":"2026072811151242000_13.1.e001770.34","first-page":"42","article-title":"Atorvastatin reduced soluble receptors of TNF-alpha in systemic lupus erythematosus","volume":"34","author":"Ferreira","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2026072811151242000_13.1.e001770.35","doi-asserted-by":"crossref","first-page":"705","DOI":"10.14423\/SMJ.0000000000000561","article-title":"Effects of Statin Therapy in Patients with Systemic Lupus Erythematosus","volume":"109","author":"Artola","year":"2016","journal-title":"South Med J"},{"key":"2026072811151242000_13.1.e001770.36","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.7150\/ijms.106393","article-title":"Associations of the Total Cholesterol\/high-density Lipoprotein Cholesterol Ratio with Outcomes in Lupus Nephritis","volume":"22","author":"Shi","year":"2025","journal-title":"Int J Med Sci"},{"key":"2026072811151242000_13.1.e001770.37","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/acr.21948","article-title":"High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus","volume":"65","author":"Campos","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026072811151242000_13.1.e001770.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2007.09.005"},{"key":"2026072811151242000_13.1.e001770.39","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11071849","article-title":"CRP Serum Levels Are Associated with High Cardiometabolic Risk and Clinical Disease Activity in Systemic Lupus Erythematosus Patients","volume":"11","author":"Pesqueda-Cendejas","year":"2022","journal-title":"J Clin Med"},{"key":"2026072811151242000_13.1.e001770.40","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/alz.13543","article-title":"Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI). Statin use moderates APOE\u2019s and CRP\u2019s associations with dementia and is associated with lesser dementia severity in \u03b54 carriers","volume":"20","author":"Royall","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2026072811151242000_13.1.e001770.41","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1093\/rheumatology\/kead416","article-title":"Role of IL-6 and IL-6 targeted therapy in systemic lupus erythematosus","volume":"62","author":"Nepal","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2026072811151242000_13.1.e001770.42","first-page":"1094","article-title":"Role of interleukin-6 and interferon-\u03b1 in systemic lupus erythematosus: A case-control study and meta-analysis","volume":"31","author":"Pattanaik","year":"2022","journal-title":"Lupus (Los Angel)"},{"key":"2026072811151242000_13.1.e001770.43","doi-asserted-by":"crossref","unstructured":"Mercader-Salvans J , Garc\u00eda-Gonz\u00e1lez M , G\u00f3mez-Bernal F , et al . Relationship between Disease Characteristics and Circulating Interleukin 6 in a Well-Characterized Cohort of Patients with Systemic Lupus Erythematosus. Int J Mol Sci 2023;24. doi:10.3390\/ijms241814006","DOI":"10.3390\/ijms241814006"},{"key":"2026072811151242000_13.1.e001770.44","doi-asserted-by":"crossref","DOI":"10.1186\/cc8135","article-title":"Statin prophylaxis and inflammatory mediators following cardiopulmonary bypass: a systematic review","volume":"13","author":"Morgan","year":"2009","journal-title":"Crit Care"},{"key":"2026072811151242000_13.1.e001770.45","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.10.7416"},{"key":"2026072811151242000_13.1.e001770.46","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10787-022-00926-y","article-title":"Effect of statins on the plasma\/serum levels of inflammatory markers in patients with cardiovascular disease; a systematic review and meta-analysis of randomized clinical trials","volume":"30","author":"Abbasifard","year":"2022","journal-title":"Inflammopharmacol"},{"key":"2026072811151242000_13.1.e001770.47","doi-asserted-by":"crossref","first-page":"104457","DOI":"10.1016\/j.cellimm.2021.104457","article-title":"Fluvastatin enhances IL-33-mediated mast cell IL-6 and TNF production","volume":"371","author":"Taruselli","year":"2022","journal-title":"Cell Immunol"},{"key":"2026072811151242000_13.1.e001770.48","first-page":"1173","article-title":"Is there still a place for erythrocyte sedimentation rate and C-reactive protein in systemic lupus erythematosus?","volume":"25","author":"Dima","year":"2016","journal-title":"Lupus (Los Angel)"},{"key":"2026072811151242000_13.1.e001770.49","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-668X(02)00741-8"},{"key":"2026072811151242000_13.1.e001770.50","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.survophthal.2016.01.001","article-title":"New developments in giant cell arteritis","volume":"61","author":"Frohman","year":"2016","journal-title":"Surv Ophthalmol"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2025-001770","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T18:15:26Z","timestamp":1785262526000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2025-001770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,9]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/lupus-2025-001770"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2025-001770","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}